Hua’s China Deal With Bayer For Novel Oral Diabetes Drug Collapses

Hua Medicine has decided to withdraw from a commercialization partnership with Bayer on HuaTangNing (dorzagliatin) in China. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Scrip